United States Skin Cancer Therapeutics Market to Grow with a CAGR of 7.24% through 2028
Rising early diagnosis and
growing public awareness for skin cancer & therapeutics is expected to
drive the United States Skin Cancer Therapeutics Market in the forecast period
2024-2028.
According to TechSci Research
report, “United states Skin Cancer Therapeutics Market – By Region,
Competition, Forecast and Opportunities, 2028”, the United States Skin
Cancer Therapeutics Market stood at USD 2.85 billion in 2022 and is anticipated
to grow with a CAGR of 7.24% in the forecast period, 2024-2028.
The increasing incidence of skin
cancer in the United States is a major trend driving the market. Factors such
as changing lifestyles, sun exposure habits, and an aging population contribute
to the rising number of skin cancer cases. As more individuals are diagnosed,
the demand for effective therapeutics continues to grow. Targeted therapy has
emerged as a highly promising approach, especially for melanoma treatment. BRAF
inhibitors, for instance, have demonstrated efficacy in treating melanomas with
specific genetic mutations. These therapies target specific molecular markers
within cancer cells, disrupting their growth while sparing healthy tissue.
Targeted therapy offers a more personalized treatment approach, resulting in
better outcomes for many patients. Combination Therapies: Researchers are
increasingly exploring combination therapies that leverage the strengths of
multiple treatment modalities. Combinations of surgery, radiation therapy,
chemotherapy, immunotherapy, and targeted therapy are tailored to individual
patient profiles, increasing the chances of successful treatment while
minimizing side effects. Clinical Trials and Research: The United States boasts
a robust clinical trial ecosystem for skin cancer research. Pharmaceutical
companies, academic institutions, and healthcare organizations are actively
conducting clinical trials to evaluate new drugs, treatment combinations, and
therapeutic approaches. This commitment to research ensures a steady flow of
innovation and options for patients. These advancements in treatment modalities
have not only improved survival rates but have also enhanced the overall
quality of life for individuals battling skin cancer. Patients now have access
to a wider range of treatment options, many of which are less invasive and
associated with fewer side effects.
The demand for more effective and
less invasive treatments has incentivized pharmaceutical companies to invest in
research and development. This has led to the creation of innovative therapies,
such as immunotherapy and targeted therapy, which have transformed the
landscape of skin cancer treatment. Key to the success of immunotherapy in skin
cancer treatment are checkpoint inhibitors such as pembrolizumab and nivolumab.
These drugs have demonstrated remarkable results in clinical trials, offering
new hope to patients with advanced melanoma. By blocking the PD-1 and PD-L1
checkpoint proteins, these drugs release the brakes on the immune system,
allowing it to recognize and attack melanoma cells. The efficacy and potential
for long-term remission associated with checkpoint inhibitors have
fundamentally transformed the prognosis for advanced melanoma patients. Researchers
are actively searching for biomarkers that can predict treatment response and
guide personalized therapeutic strategies. These biomarkers help tailor
treatment plans to individual patients, optimizing their chances of success. Also,
Immunotherapy, particularly checkpoint inhibitors, has seen significant
investment in research. These treatments have shown remarkable success in
treating advanced melanoma and are being explored for use in other skin cancer
types.
Browse over XX market data
Figures spread through XX Pages and an in-depth TOC on "United States Skin Cancer Therapeutics Market”
Based on Cancer Type the market
is segmented into Melanoma, Non-melanoma, and Others. In 2022, the United
States Skin Cancer Therapeutics Market was dominated by the non-melanoma
segment and is predicted to continue expanding over the coming years. This is
attributed due to the rising incidence of non-melanoma skin cancers and the
increasing adoption of effective treatments. Non-melanoma skin cancers, which
primarily include basal cell carcinoma and squamous cell carcinoma, are the
most common types of skin cancer worldwide. Several factors contribute to the
dominance and continued growth of the non-melanoma segment in the United States
Skin Cancer Therapeutics market including high incidence rates, better
treatment options, topical therapies and availability of early detection and
diagnosis, etc.
Non-melanoma skin cancers account
for the majority of skin cancer cases diagnosed each year. Their high incidence
rates are driven by factors such as prolonged sun exposure, aging populations,
and changing lifestyles. ver the years, there have been significant
advancements in the treatment of non-melanoma skin cancers. These advancements
include minimally invasive surgical techniques, topical therapies, and
radiation therapy. These treatment options offer favorable outcomes for
patients, increasing their adoption rates. Improved awareness and screening
efforts have led to the early detection and diagnosis of non-melanoma skin
cancers. Early-stage cancers are more likely to be treated successfully,
further contributing to the segment's growth. Additionally, non-melanoma skin
cancers are often treated with topical therapies, which are highly effective
for certain cases. Topical treatments, such as imiquimod and fluorouracil, are
non-invasive and have demonstrated excellent outcomes for patients with superficial
skin cancers.
Based on type the market is
segmented into diagnosis and Therapeutics. In 2022, the United States Skin
Cancer Therapeutics Market was dominated by the Diagnosis segment and is
predicted to continue expanding over the coming years. This is attributed to
the the increasing emphasis on early detection and diagnosis in the fight
against skin cancer. Skin cancer, when diagnosed at an early stage, is highly
treatable and often curable. As a result, there has been a growing emphasis on
regular skin checks and screening programs to detect skin cancer at its
earliest, most manageable stage. The incidence of skin cancer, including both
melanoma and non-melanoma types, has been on the rise. Factors such as
increased sun exposure, tanning bed use, and an aging population contribute to
this trend. The higher prevalence of skin cancer cases necessitates a greater
focus on diagnosis.
Moreover, Public awareness
campaigns, including Skin Cancer Awareness Month and educational initiatives,
have encouraged individuals to be proactive in monitoring their skin for
changes. These campaigns stress the importance of early detection, prompting
more people to seek medical evaluation for suspicious moles or lesions. Access
to Dermatological Services: Improved access to dermatological care plays a
pivotal role in the diagnosis segment's growth. The availability of
dermatologists and skin cancer specialists enables individuals to undergo
regular skin checks and receive timely evaluations, leading to earlier
diagnoses.
In 2022, the United States Skin Cancer
Therapeutics Market was dominated by the Mid-West segment and is predicted to
continue expanding over the coming years. Firstly, the Mid-West region boasts a
significant population, and within that population, there is an increasing
awareness of the importance of early detection and treatment of skin cancer.
This heightened awareness has led to more regular screenings and early
interventions, which can significantly impact the market's growth. These
efforts have increased public awareness about the importance of regular skin
checks, sun protection, and early detection. Consequently, more individuals in
the region are seeking medical attention for suspicious skin changes, leading
to earlier diagnoses. Moreover, the Mid-West is home to world-class healthcare
facilities and research institutions dedicated to cancer care. These
institutions conduct cutting-edge research, clinical trials, and treatment
innovations, making them focal points for patients seeking the best possible
care.
Major companies operating in United
states Skin Cancer Therapeutics Market are:
- Abbott
Laboratories
- Amgen, Inc.
- Pfizer Inc.
- Bristol-Myers
Squibb Company
- F. Hoffmann-La
Roche Ltd
- Merck & Co.,
Inc.
- Sanofi S.A.
- Sun
Pharmaceutical Industries Ltd
- Daiichi Sankyo
Company, Limited
- Sirnaomics, Inc
Download Free Sample Report
Customers can also request
for 10% free customization on this report.
“The United States Skin Cancer
Therapeutics market is driven by several compelling factors that collectively
contribute to its rapid growth and innovation in the healthcare industry.
Firstly, major factor contributing to the significant growth of the United
States Skin Cancer Therapeutics Market in the coming years is the continuous
advancement in treatment modalities and breakthroughs in medical research. Targeted therapy has revolutionized the
treatment of skin cancer, particularly melanoma. These therapies specifically
target the genetic mutations or abnormalities present in cancer cells, sparing
healthy tissue. As researchers continue to identify new genetic markers and
pathways, the range of targeted therapies is likely to expand. Additionally, Skin
cancer surgeries, such as Mohs micrographic surgery, have become more precise
and less invasive. These techniques result in better cosmetic outcomes and reduced
post-operative scarring, enhancing the patient experience and foster the demand
for United states Skin Cancer Therapeutics Market in the forecast period” said
Mr. Karan Chechi, Research Director with TechSci Research, a research-based
management consulting firm.
“United States Skin
Cancer Therapeutics Market By Cancer Type (Melanoma, Non-melanoma, Others), By
Type (Diagnosis, {Dermatoscopy, Biopsy, Genetic Tests, Others}, Therapeutics
{Chemotherapy, Immunotherapy, Targeted Therapy, Others}), By Region, Competition Forecast &
Opportunities, 2028” has evaluated the
future growth potential of United states Skin Cancer Therapeutics Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in United states Skin Cancer Therapeutics Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email:
[email protected]
Website:
https://www.techsciresearch.com